一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

ChemicalBook >> journal list >> Kidney Diseases >>article
Kidney Diseases

Kidney Diseases

IF: 3.2
Download PDF

Roxadustat for Patients with Post-transplant Anemia: A Narrative Review

Published:10 November 2023 DOI: 10.1159/000535071
Xiaoxiao Tang, Fei Liu, Qiuyu Li, Jianhua Mao

Abstract

Background: Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) are novel oral agents used for renal anemia treatment. Roxadustat, a first-in-class HIF-PHI used for treating anemia in chronic kidney disease patients, has been approved in China, Japan, South Korea, Chile, and Europe. Roxadustat is involved in HIF degradation, which can stimulate endogenous erythropoietin (EPO) production and improve iron utilization. Besides, roxadustat can promote dietary iron uptake and transport. In comparison with traditional erythropoiesis-stimulating agent (ESA) treatment, it might reduce cardiovascular risk and mortality as it causes only a slight increase in the plasma EPO level. Phase II and III clinical trial reports have shown that roxadustat is effective for treating chronic kidney disease patients. The role of roxadustat in kidney transplant recipients (KTRs) needs to be examined as patients with chronic kidney disease are different from those receiving renal transplants. Summary: Clinical trials have demonstrated that roxadustat effectively increases and maintains hemoglobin levels in patients with dialysis-dependent and non-dialysis-dependent chronic kidney disease by stimulating endogenous EPO production and optimizing iron utilization. Roxadustat has recently been used effectively to treat patients with EPO-resistant anemia. It has also been used for treating patients with post-transplant anemia (PTA), which is a prognostic factor for mortality in kidney transplant recipients with an iron deficiency and impaired glomerular filtration rate. Here, we examined the findings of four studies in a narrative review and discussed our perspectives regarding this field of study. Key Messages: Roxadustat significantly improves hemoglobin levels without affecting renal function in KTRs with PTA. It also enhances iron utilization by decreasing ferritin and hepcidin levels and increasing total iron binding capacity, transferrin, and serum iron levels. Roxadustat ameliorates anemia and inflammation, and might have reno-protective effects in KTRs.

Substances (6)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Roxadustat 808118-40-3 C19H16N2O5 414 suppliers $28.00-$6800.00
Ferritin 79468-83-0 61 suppliers Inquiry
EPO 56 suppliers $366.00-$2489.00
TRANSFERRIN 33 suppliers $302.00-$732.00
hepcidin 9 suppliers Inquiry
serum iron 1 suppliers Inquiry

Similar articles

IF:5.4

Roxadustat: Not just for anemia.

ACS Applied Energy Materials Xiaoyu Zhu, Lili Jiang,etc Published: 29 August 2022
IF:16.4

Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients.

Accounts of Chemical Research Tadao Akizawa, Yusuke Yamaguchi,etc Published: 1 October 2021
边坝县| 锡林浩特市| 怀化市| 股票| 黑龙江省| 临湘市| 阿鲁科尔沁旗| 禹城市| 陆河县| 桓台县| 蓝山县| 平塘县| 台东县| 青阳县| 分宜县| 元阳县| 夏邑县| 滁州市| 大宁县| 巴楚县| 文安县| 凤山县| 板桥市| 台中县| 定陶县| 科尔| 永和县| 上高县| 措美县| 宜都市| 房产| 包头市| 巴彦县| 双牌县| 四平市| 甘谷县| 无棣县| 屯门区| 天峨县| 锡林郭勒盟| 太仓市|